On July the 21st the MSUD Board of Directors traveled to Bethesda, Maryland for our annual Board meeting. We stayed at the Hyatt Regency in Bethesda. The location and hotel was selected for two reasons: We would be meeting with a scientist from the National Institute of Health (NIH) and we wanted to check out the hotel as a possible future Symposium site.

On Friday afternoon we met with Tom Eggerman, MD PhD, Program Director of the Division of Diabetes, Endocrine, and Metabolic Disease at the NIH. Our goal was to be better informed about the workings of the NIH and the way in which they secure funding for research. He advised us that the best way to get financial support is through Congress. As an example he noted that funding for Type 1 diabetes research is mandated by Congress. He recommended that we take this approach, either by contacting our own congressperson or those who serve on a specific committee. With a mandate to fund research related to MSUD, the NIH could then put out a request for proposals (RFP). He noted during our meeting that for the first time the FDA has approved gene therapy for leukemia. He noted that there is currently no research specific to MSUD in their rare disease portfolio. We were pleased and felt our time with him was well spent.

After our meeting with Dr. Eggerman we convened for our board meeting, which we continued the next day. Our first order of business was the election of officers. The following officers were elected:

  • President: Ivan Martin
  • Vice President: Sandy Bulcher
  • Treasurer: Dave Bulcher
  • Secretary: Karen Dolins

The remainder of the meeting focused primarily on two areas: finalizing a business plan and developing a patient registry.

A clearly conceived business plan is essential to moving our organization forward. Our business plan identifies 4 broad goals:

  1. To connect with families and professionals
  2. To promote research
  3. To engage in advocacy
  4. To develop a fundraising plan which will allow us to achieve our goals

  5. Development of a patient registry is an important step in promoting research for MSUD. The board decided to partner with Emory University and their NBS Connect which has developed a registry. Sandy Bulcher and Karen Dolins will be meeting with Dr. Rani Singh who spearheads this effort at Emory to finalize the details. Please see the article on page 16 which further describes the Registry.

    Thank you for your continued support and don’t forget to mark your calendars for the next Symposium in Pittsburg, Pa. on June 28th thru the 30th 2018. I hope to see you there!

Sweet Odyssey

Artur Santos was born on January 18, 2002, the second son of Soraya and Idario Santos. They never imagined how their lives were about change as the second baby arrived.

Read More

In The Professional Journals

A Patient with MSUD: Acute Management with Sodium Phenylacetate/Sodium Benzoate and Sodium Phenylbutyrate

Read More

Adjusting Protein In An Adult With MSUD

A little over a year ago, in January, Jeff was just not himself. He had limited energy, was not eating well, and often appeared slightly agitated.

Read More

NBS-MSUD Connect: Advancing MSUD Research And More


Rare disease registries have received attention in recent years because of the many ways in which they can benefit the rare disease community.

Read More


As our legislators headed home for their August break, Rare Disease Legislative Advocates got busy.

Read More

My Trip To Israel

I met Avi, Dikla, and Tamar Starr last year at the MSUD Symposium in Raleigh, NC. Tamar, classic MSUD, was 2 ½ at the time, and they invited me to come to Israel and stay with them for a year.

Read More


A Child's Life

Subscribe to our mailing list

Signup To Our Newsletter Signup with your email address to receive news and updates